 Interleukin-2
"Interleukin-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
| Descriptor ID |
D007376
|
| MeSH Number(s) |
D12.644.276.374.465.021 D12.644.276.374.480.372 D12.776.467.374.465.021 D12.776.467.374.480.372 D23.529.374.465.155 D23.529.374.480.372
|
| Concept/Terms |
Interleukin-2- Interleukin-2
- Interleukin 2
- IL-2
- IL2
- TCGF
- Interleukine 2
- Lymphocyte Mitogenic Factor
- Mitogenic Factor, Lymphocyte
- T-Cell Growth Factor
- T Cell Growth Factor
- T-Cell Stimulating Factor
- T Cell Stimulating Factor
- Thymocyte Stimulating Factor
- Interleukin II
Ro-23-6019- Ro-23-6019
- Ro 23 6019
- Ro236019
- Ro-236019
- Ro 236019
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-2".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-2".
This graph shows the total number of publications written about "Interleukin-2" by people in this website by year, and whether "Interleukin-2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 3 | 5 | | 1996 | 2 | 4 | 6 | | 1997 | 3 | 4 | 7 | | 1998 | 3 | 11 | 14 | | 1999 | 4 | 6 | 10 | | 2000 | 3 | 3 | 6 | | 2001 | 4 | 6 | 10 | | 2002 | 0 | 4 | 4 | | 2003 | 3 | 5 | 8 | | 2004 | 4 | 7 | 11 | | 2005 | 1 | 8 | 9 | | 2006 | 1 | 2 | 3 | | 2007 | 6 | 4 | 10 | | 2008 | 5 | 3 | 8 | | 2009 | 2 | 7 | 9 | | 2010 | 5 | 4 | 9 | | 2011 | 2 | 0 | 2 | | 2012 | 3 | 5 | 8 | | 2013 | 2 | 2 | 4 | | 2014 | 5 | 6 | 11 | | 2015 | 1 | 5 | 6 | | 2016 | 2 | 5 | 7 | | 2017 | 3 | 2 | 5 | | 2018 | 0 | 6 | 6 | | 2019 | 1 | 3 | 4 | | 2020 | 3 | 3 | 6 | | 2021 | 1 | 1 | 2 | | 2022 | 2 | 5 | 7 | | 2023 | 1 | 2 | 3 | | 2024 | 0 | 2 | 2 | | 2025 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-2" by people in Profiles.
-
Cabrera-Martinez B, Garcia-Perez JE, Baxter RM, Lui VG, Ghosh T, Eken A, Kostka-Newman Z, Garcia JRM, Rahkola J, Gessner RL, Dutmer CM, Klarquist J, Pietras EM, Ghosh D, Johnson SA, Kedl RM, Hsieh EWY. A hypomorphic Il2rb mutant mouse model recapitulates and reveals mechanisms of human T cell immune dysregulation in IL-2Rß deficiency. Cell Rep. 2025 Jul 22; 44(7):115902.
-
Lowery FJ, Goff SL, Gasmi B, Parkhurst MR, Ratnam NM, Halas HK, Shelton TE, Langhan MM, Bhasin A, Dinerman AJ, Dulemba V, Goldlust IS, Gustafson AM, Hakim AA, Hitscherich KJ, Kenney LM, Levy L, Rault-Wang JG, Bera A, Ray S, Seavey CD, Hoang CD, Hernandez JM, Gartner JJ, Sindiri S, Prickett TD, McIntyre LS, Krishna S, Robbins PF, Klemen ND, Kwong MLM, Yang JC, Rosenberg SA. Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. Nat Med. 2025 Jun; 31(6):1994-2003.
-
Wang Z, Ramakrishna R, Wang Y, Qiu Y, Ma J, Mintzlaff D, Zhang H, Li B, Hammell B, Lucia MS, Pomfret E, Su AA, Washington KM, Mathes DW, Wang Z. Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-IL2 bispecific immunotoxin in rats and minipigs. Eur J Pharmacol. 2024 Apr 05; 968:176408.
-
Borgers JSW, van Schijndel AW, van Thienen JV, Klobuch S, Seijkens TTP, Tobin RP, van Heerebeek L, Driessen-Waaijer A, Rohaan MW, Haanen JBAG. Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned. ESMO Open. 2024 Feb; 9(2):102383.
-
Thompson B, Strange A, Amato CM, Hester-McCullough J, Sarnaik AA, Weber JS, Woods DM. CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy. J Immunol. 2023 09 01; 211(5):735-742.
-
Gadwa J, Amann M, Bickett TE, Knitz MW, Darragh LB, Piper M, Van Court B, Bukkapatnam S, Pham TT, Wang XJ, Saviola AJ, Deak LC, Umaña P, Klein C, D'Alessandro A, Karam SD. Selective targeting of IL2Rß? combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC. Cell Rep Med. 2023 08 15; 4(8):101150.
-
Wang Z, Ma J, Zhang H, Ramakrishna R, Mintzlaff D, Mathes DW, Pomfret EA, Lucia MS, Gao D, Haverkos BM, Wang Z. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023 07; 13(7):1309-1319.
-
Piper M, Hoen M, Darragh LB, Knitz MW, Nguyen D, Gadwa J, Durini G, Karakoc I, Grier A, Neupert B, Van Court B, Abdelazeem KNM, Yu J, Olimpo NA, Corbo S, Ross RB, Pham TT, Joshi M, Kedl RM, Saviola AJ, Amann M, Umaña P, Codarri Deak L, Klein C, D'Alessandro A, Karam SD. Simultaneous targeting of PD-1 and IL-2Rß? with radiation therapy inhibits pancreatic cancer growth and metastasis. Cancer Cell. 2023 05 08; 41(5):950-969.e6.
-
Qiu Y, Qi Z, Wang Z, Cao Y, Lu L, Zhang H, Mathes D, Pomfret EA, Lu SL, Wang Z. EGF-IL2 bispecific and bivalent EGF fusion toxin efficacy against syngeneic head and neck cancer mouse models. Oncol Rep. 2023 Feb; 49(2).
-
Palanki R, Swingle KL, Mitchell MJ. A (Controlled) Spill of IL2 for Localized Treatment of Mesothelioma. Clin Cancer Res. 2022 12 01; 28(23):5010-5012.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|